Efficacy observation of anaplastic lymphoma kinase-tyrosine kinase inhibitors in treatment of inflammatory myofibroblastic tumor
10.3760/cma.j.cn115355-20201111-00628
- VernacularTitle:间变性淋巴瘤激酶-酪氨酸激酶抑制剂治疗炎性肌纤维母细胞瘤效果观察
- Author:
Jiamei CHEN
1
;
Bo LUO
;
Xixi LUO
;
Qiong WANG
;
Wei SHI
;
Gaoke CAI
;
Wensi ZHAO
;
Hao CHENG
;
Yongshun CHEN
Author Information
1. 武汉大学第一临床学院 武汉大学人民医院肿瘤中心，武汉 430060
- Keywords:
Neoplasms, muscle tissue;
Inflammatory myofibroblastic tumor;
Anaplastic lymphoma kinase;
Tyrosine kinase inhibitor;
Crizotinib
- From:
Cancer Research and Clinic
2021;33(8):585-590
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKI) in treatment of inflammatory myofibroblastic tumor (IMT).Methods:The clinicopathological data of one recurrent abdominal IMT patient in Renmin Hospital of Wuhan University in 2018 were retrospectively analyzed. The clinicopathological and molecular characteristics, ALK-TKI treatment efficacy and prognosis of 41 patients with IMT reported in the literature from January 2010 to August 2020 were systematically reviewed.Results:This patient with abdominal IMT in Renmin Hospital of Wuhan University was a 27-year-old female who relapsed 2 months after surgery. Chemotherapy combined with bevacizumab was ineffective. After oral administration of crizotinib, the condition resolved after 1 month, and complete remission (CR) was achieved after 29 months. The median age of onset of 41 IMT cases reported in the literature was 22 years old (0-61 years old), of which 32 cases (78.0%) had multiple organ involvement, all of which had recurrence or metastasis. There were 38 cases of ALK mutation and 3 cases of TFG-ROS1 fusion gene-positive. Thirty-four patients treated with crizotinib in the first-line treatment of ALK-TKI, and the median resistance time of crizotinib was 8 months (2-48 months). The total clinical benefit rate of ALK-TKI was 85.3% (29/34), and 20 patients achieved CR. The median time for the first CR was 11 months (4-36 months), and the median duration time of medication for CR patients was 19.5 months (2-60 months). The median progression-free survival (PFS) time of 24 patients who underwent surgery and/or chemotherapy and radiotherapy was 4 months (1-45 months); after progression, ALK-TKI treatment was performed, and the median PFS time was 14 months (3-62 months).Conclusions:IMT is a true neoplasm with characteristics of recurrence and metastasis. Reasonable combination of ALK-TKI with surgery, radiotherapy and chemotherapy can improve the prognosis of IMT patients.
